• Envoy Medical’s third-quarter 2026 net loss attributable to common stockholders narrowed 32% year over year to $5.24 million.
• Net revenue rose 57% to $66,000, while cash totaled $14.57 million at September 30, 2026.
• Following quarter-end, all 56 Acclaim trial patients surpassed six-month follow-up, and the second FDA approval application module was submitted.
• All Stage 2 participants are expected to complete 12-month data collection by early second-quarter 2027, with final submission planned months later.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611050700NEWSFILECNPR____20261105_322572_1) on November 05, 2026, and is solely responsible for the information contained therein.